Key result
ICV infusion of MAPK inhibitors (PD98059 or SP600125) or losartan decreased AT(1)-R protein and mRNA in the hypothalamus of rats with heart failure, indicating MAPKs mediate AT(1)-R upregulation.
MAPKs p44/42 and c-Jun N-terminal kinase mediate the upregulation of hypothalamic AT1 receptors in rats with heart failure, suggesting Ang II upregulates its own receptor via this pathway.
Answers are grounded in this paper and cite their sources.
May implicate hypothalamic MAPKs in HF-related AT1-R upregulation; leaves open clinical translation to sympathetic modulation.
In heart failure (HF), angiotensin II type 1 receptor (AT(1)-R) expression is upregulated in brain regions regulating sympathetic drive, blood pressure, and body fluid homeostasis. However, the mechanism by which brain AT(1)-R are upregulated in HF remains unknown. The present study examined the hypothesis that the angiotensin II (Ang II)-triggered mitogen-activated protein kinases (MAPKs) p44/42, p38, and c-Jun N-terminal kinase contribute to upregulation of the AT(1)-R in the hypothalamus of rats with HF. AT(1)-R protein, AT(1)-R mRNA, and AT(1)-R immunoreactivity increased in the paraventricular nucleus of hypothalamus and the subfornical organ of rats with ischemia-induced HF compared with sham-operated controls. Phosphorylated p44/42 MAPK, c-Jun N-terminal kinase, and p38 MAPK also increased in paraventricular nucleus and subfornical organ. A 4-week ICV infusion of the AT(1)-R antagonist losartan decreased AT(1)-R protein and phosphorylation of p44/42 MAPK, c-Jun N-terminal kinase, and p38 MAPK in the HF rats. A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not. Treatment with ICV losartan, PD98059, and SP600125 had no effect on AT(1)-R expression by Western blot in sham-operated rats. In untreated HF rats 4 weeks after coronary ligation, a 3-hour ICV infusion of PD98059, SP600125, or losartan reduced AT(1)-R mRNA in paraventricular nucleus and subfornical organ. These data indicate that MAPK plays an important role in the upregulation of AT(1)-R in the rat forebrain in HF and suggest that Ang II upregulates its own receptor by this mechanism.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2008) studied Heart failure. ICV infusion of losartan, PD98059, or SP600125 vs. Sham-operated controls or untreated HF rats was evaluated on AT(1)-R protein, mRNA, and immunoreactivity in the paraventricular nucleus and subfornical organ. ICV infusion of MAPK inhibitors (PD98059 or SP600125) or losartan decreased AT(1)-R protein and mRNA in the hypothalamus of rats with heart failure, indicating MAPKs mediate AT(1)-R upregulation.
Synapse has enriched 10 related papers. Consider them for comparative context: